

**Supplementary Table 2.** Depression-Associated SNP Identified in the WLS

Gene	Encodes	SNP	Alleles	Chr#/Location	Residue	Associated disease/behavior
<i>ACVR2B</i>	activin receptor IIB	rs3749386	T/C	3/intron 1	--	left-right axis malformations*(1)
<i>APOC3</i>	apolipoprotein C-III	rs2854116	T/C	11/promoter (-455)	--	nonalcoholic fatty liver disease(2)
<i>DRD2/ANKK1</i>	dopamine receptor D2/ankyrin repeat and kinase domain containing 1	rs1800497	C/T	11/exon (ANKK1)	Glu713Lys	obesity, drug addiction (3)
<i>DRD2</i>	dopamine receptor D2	rs2242592	T/C	11/3'	--	schizophrenia (4)
<i>FTO</i>	fat mass and obesity associated	rs1421085	T/C	16/intron 1	--	obesity (5-7), mental disorders (8)
<i>GNRH1</i>	gonadotropin-releasing hormone	novel SNP	T/C	8/promoter	--	Alzheimer's disease (9)
<i>IL6</i>	interleukin 6	rs1800795	C/G	7/promoter (-174)	--	arthritis (10), breast cancer (11), diabetes (12), depression (13)

Gene association only

## References

1. Kosaki R, Gebbia M, Kosaki K, Lewin M, Bowers P, Towbin JA, et al. Left–right axis malformations associated with mutations in ACVR2B, the gene for human activin receptor type IIB. *American Journal of Medical Genetics*. 1999;82(1):70-6.
2. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang X-M, et al. Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease. *New England Journal of Medicine*. 2010;362(12):1082-9.
3. Blum K, Braverman ER, Wood RC, Gill J, Li C, Chen TJ, et al. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. *Pharmacogenetics*. 1996 Aug;6(4):297-305.
4. Dubertret C, Bardel C, Ramoz N, Martin P-M, Deybach J-C, Adès J, et al. A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2010;34(3):492-9.
5. Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. *Nat Genet*. 2007;39(6):724-6.
6. Tung Y-CL, Yeo GSH. From GWAS to biology: lessons from FTO. *Annals of the New York Academy of Sciences*. 2011;1220(1):162-71.
7. Chabris C, Hebert B, Benjamin D, Beauchamp J, Cesarini D, van der Loos M, et al. Most reported genetic associations with general intelligence are probably false positives. *Psychological Science*. 2011;In press.
8. Kivimaki M, Jokela M, Hamer M, Geddes J, Ebmeier K, Kumari M, et al. Examining Overweight and Obesity as Risk Factors for Common Mental Disorders Using Fat Mass and Obesity-Associated (FTO) Genotype-Instrumented Analysis. *Am J Epidemiol*. 2011 Feb 15;173(4):421-9.
9. Wilson AC. Investigations into gonadotropin-releasing hormone receptor signaling in extrahypothalamic neurons of the brain: Implications for normal cognition and the pathogenesis of Alzheimer's disease: Thesis. University of Wisconsin, Madison, USA; 2009.
10. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *The Journal of Clinical Investigation*. 1998;102(7):1369-76.
11. Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB, et al. Modifying Effects of IL-6 Polymorphisms on Body Size-Associated Breast Cancer Risk. *Obesity*. 2008;16(2):339-47.
12. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK, et al. IL6 Gene Promoter Polymorphisms and Type 2 Diabetes. *Diabetes*. 2006 October 2006;55(10):2915-21.
13. Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. *Mol Psychiatry*. 2009 Dec;14(12):1095-104.